Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.

@article{Ball2014AdditionOA,
  title={Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.},
  author={William A. Ball and Duane B. Snavely and Richard Hargreaves and Armin Szegedi and Christopher Lines and Scott A. Reines},
  journal={Human psychopharmacology},
  year={2014},
  volume={29 6},
  pages={
          568-77
        }
}
  • William A. Ball, Duane B. Snavely, +3 authors Scott A. Reines
  • Published in Human psychopharmacology 2014
  • Psychology, Medicine
  • OBJECTIVE Aprepitant is a neurokinin 1 receptor antagonist approved for prevention of chemotherapy-induced and post-operative nausea and vomiting. Early studies demonstrated promising antidepressant activity as monotherapy, although this was unsupported by subsequent phase 3 trials. This phase 2 study evaluated whether aprepitant potentiated the antidepressant effects of paroxetine. METHODS Outpatients with major depressive disorder were randomized to aprepitant 200 mg + paroxetine 20 mg… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    1
    Twitter Mention

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 11 CITATIONS

    Brain neurokinin-1 receptor availability in never-medicated patients with major depression - A pilot study.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    New targets for rapid antidepressant action

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 25 REFERENCES

    Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.

    VIEW 7 EXCERPTS
    HIGHLY INFLUENTIAL

    Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.

    VIEW 2 EXCERPTS